Depression comorbid with anxiety or medical illness: The role of paroxetine

International Journal of Psychiatry in Clinical Practice

Volumn 5, Issue 1, 2001, Pages 3-10

  Rouillon, F ^a  

^a Hopital Albert Chenevier   (France)

Author keywords

Anxiety disorders; Comorbid depression; Medical illness; Paroxetine

Indexed keywords

AMITRIPTYLINE; AMOBARBITAL; CENTRAL DEPRESSANT AGENT; CIMETIDINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; OXAZEPAM; PAROXETINE; PHENYTOIN; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; HUMAN; OBSESSION; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SOCIAL PHOBIA; SUICIDE;

EID: 0035043644     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/136515001300225132     Document Type: Review

References (83)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States
2. Depression in the community: The first pan-European study DEPRES (Depression Research in European Society)
3. Depression and chronic medical illness
4. The broad spectrum of comorbid depression: Implications for treatment
5. Lifetime comorbidity of panic attacks and major depression in a population-based study: Symptom profiles
6. A multicentre double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression
7. The advantages of paroxetine in different subgroups of depression
8. Effects of paroxetine in depressed adolescents
9. Adolescent depression: Efficacy of paroxetine
10. Paroxetine in the elderly depressed patient: Randomized comparison with fluoxetine of efficacy, cognitive and behavioral effects
11. Treatment of depression in late life
12. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
13. The pre-therapeutic classification of comorbidity in chronic disease
14. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus
15. Anxiety reconceptualized
16. Panic disorder and social phobia: Possible implications of comorbid depression for drug therapy
17. Lifetime panic-depression comorbidity in the National Comorbidity Survey
18. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the U.S. National Comorbidity Survey
19. Agoraphobia, simple phobia and social phobia in the National Comorbidity Survey
20. Pharmacotherapy of panic disorder: Differential efficacy from a clinical viewpoint
21. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis
22. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study
23. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
24. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
25. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder
26. The long-term efficacy and safety of paroxetine in panic disorder
27. Efficacy studies of paroxetine in panic disorder
28. The cross-national epidemiology of obsessive compulsive disorder
29. Comorbid depression and anxiety spectrum disorders
30. Serotonergic antidepressants and their efficacy in obsessive compulsive disorder
31. Obsessive-compulsive disorder: A new perspective in diagnosis and treatment
32. A fixed-dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder
33. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD paroxetine study investigators
34. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder
35. Long-term treatment and prevention of relapse in OCD with paroxetine
36. Classification and epidemiology of social phobia
37. The epidemiology of social phobia: Findings from the Duke epidemiological catchment area study
38. Paroxetine treatment of generalised social phobia (social anxiety disorder). A randomised controlled trial
39. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study
40. Psychiatric disorder in medical inpatients
41. The nature and course of depression following myocardial infarction
42. Major depressive disorder predicts cardiac events in patients with coronary artery disease
43. Perspectives on the relationship between cardiovascular disease and affective disorder
44. Depression and acute myocardial infarction: A review and reinterpretation
45. Risks of antidepressants in the elderly. Tricyclic antidepressants and arrhythmias - Revising risks
46. Cardiovascular effects of antidepressants. Avoiding cardiotoxicity in the elderly
47. Preliminary report: Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction
48. Heart rate variability in depressed patients and differential effects of paroxetine and amitriptyline on cardiovascular autonomic functions
49. The effect of amitriptyline, doxepin, fluoxamine, and paroxetine treatment on heart rate variability
50. Comparison of paroxetine and nortriptyline in depressed patients with ischaemic heart disease
51. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis
52. The implications of depression for pain and disability in rheumatoid arthritis
53. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states
54. Antidepressants in the management of chronic pain syndromes
55. Antidepressant analgesia in rheumatoid arthritis
56. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain
57. Depression associated with rheumatoid arthritis - Comparison of paroxetine and amitriptyline
58. Depressive mood disorders in patients with operable breast cancer
59. Psychiatric disorder in patients with advanced breast cancer: Prevalence and associated factors
60. Depression in breast cancer patients - Comparison of paroxetine and amitriptyline
61. Depression and Parkinson's disease: A review
62. Depression in Parkinson's disease: A biochemical and organic viewpoint
63. A survey of antidepressant drug use in Parkinson's disease
64. Serotonin syndrome and the combined use of deprenyl and antidepressant in Parkinson's disease
65. Serotonin syndrome in Parkinson disease
66. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
67. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
68. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders
69. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
70. An interaction study of paroxetine on lithium plasma levels in depressed patients stabilized on lithium therapy
71. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor
72. The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam or alcohol
73. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors
74. Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine, or noradrenaline re-uptake
75. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin
76. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease
77. Clinical characteristics of patients with concurrent major depressive disorder and panic disorder
78. Panic and depression: A worldwide primary care perspective
79. Comorbidity of panic and major depressive disorder
80. Medical comorbidity of major depressive disorder in a primary medical practice
81. Where are we going with SSRIs?
82. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease
83. Treatment of depression in patients with heart disease